Betty Y S Kim

List of Publications by Year
in descending order

59 papers	9,109 citations	134610 34 h-index	145109 60 g-index
62 all docs	62 docs citations	62 times ranked	17036 citing authors

#	Article	IF	Citations
1	Challenges and opportunities of nanotechnology in cancer immunotherapy. , 2022, , 197-239.		1
2	Strategies of Perturbing Ion Homeostasis for Cancer Therapy. Advanced Therapeutics, 2022, 5, 2100189.	1.6	3
3	Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nature Communications, 2022, 13, 767.	5.8	128
4	Cancer nanomedicines for enhanced immunotherapy. , 2022, , .		0
5	Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors. Cancer Research Communications, 2022, 2, 402-416.	0.7	2
6	Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Nature Nanotechnology, 2022, 17, 891-899.	15.6	74
7	Immune landscape of a genetically engineered murine model of glioma compared with human glioma. JCI Insight, 2022, 7, .	2.3	10
8	Harnessing cGASâ€STING Pathway for Cancer Immunotherapy: From Bench to Clinic. Advanced Therapeutics, 2022, 5, .	1.6	2
9	Considerations for designing preclinical cancer immune nanomedicine studies. Nature Nanotechnology, 2021, 16, 6-15.	15.6	77
10	Vascular ApoE4 Impairs Behavior by Modulating Gliovascular Function. Neuron, 2021, 109, 438-447.e6.	3.8	42
11	Spatiotemporal Immunomodulation Using Biomimetic Scaffold Promotes Endochondral Ossificationâ€Mediated Bone Healing. Advanced Science, 2021, 8, e2100143.	5.6	33
12	Self-Assembled pH-Sensitive Polymeric Nanoparticles for the Inflammation-Targeted Delivery of Cu/Zn-Superoxide Dismutase. ACS Applied Materials & Interfaces, 2021, 13, 18152-18164.	4.0	14
13	Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy. Advanced Materials, 2021, 33, e2007576.	11.1	42
14	Advanced Immunotherapy Approaches for Glioblastoma. Advanced Therapeutics, 2021, 4, 2100046.	1.6	8
15	Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clinical Cancer Research, 2020, 26, 1712-1724.	3.2	76
16	Nanotechnology platforms for cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1590.	3.3	82
17	Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nature Biomedical Engineering, 2020, 4, 69-83.	11.6	415
18	The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update. Journal of Neuro-Oncology, 2020, 150, 215-267.	1.4	19

#	Article	IF	Citations
19	Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nature Communications, 2020, 11, 1508.	5.8	138
20	Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy. Frontiers in Oncology, 2020, 10, 606906.	1.3	36
21	Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. JAMA Network Open, 2020, 3, e2028627.	2.8	22
22	Tumor Vasculatures: A New Target for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2019, 40, 613-623.	4.0	79
23	On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology, 2019, 14, 629-635.	15.6	149
24	Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel. Cancers, 2019, 11, 1571.	1.7	34
25	Membrane TLR9 Positive Neutrophil Mediated MPLA Protects Against Fatal Bacterial Sepsis. Theranostics, 2019, 9, 6269-6283.	4.6	22
26	Phagocytosis checkpoints as new targets for cancer immunotherapy. Nature Reviews Cancer, 2019, 19, 568-586.	12.8	557
27	Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery. Advanced Science, 2019, 6, 1802070.	5.6	82
28	Visualization of Hepatocellular Regeneration in Mice After Partial Hepatectomy. Journal of Surgical Research, 2019, 235, 494-500.	0.8	6
29	The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clinical Cancer Research, 2019, 25, 1709-1717.	3.2	95
30	Improving immuneâ€“vascular crosstalk for cancer immunotherapy. Nature Reviews Immunology, 2018, 18, 195-203.	10.6	340
31	Study of Osteocyte Behavior by High-Resolution Intravital Imaging Following Photo-Induced Ischemia. Molecules, 2018, 23, 2874.	1.7	2
32	How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. Nature Biomedical Engineering, 2018, 2, 797-809.	11.6	99
33	Immunomodulating Nanomedicine for Cancer Therapy. Nano Letters, 2018, 18, 6655-6659.	4.5	121
34	Perspectives of Nanotechnology in the Management of Gliomas. Progress in Neurological Surgery, 2018, 32, 196-210.	1.3	4
35	Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. Journal of Clinical Investigation, 2018, 128, 2104-2115.	3.9	152
36	Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering, 2017, 1, .	11.6	178

#	Article	IF	Citations
37	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nature Nanotechnology, 2017, 12, 763-769.	15.6	136
38	Lessons from immuno-oncology: a new era for cancer nanomedicine?. Nature Reviews Drug Discovery, 2017, 16, 369-370.	21.5	37
39	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiotherapy and Oncology, 2017, 125, 80-88.	0.3	58
40	S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma. Cancer Research, 2017, 77, 5360-5373.	0.4	78
41	Breaking Down the Barriers to Precision Cancer Nanomedicine. Trends in Biotechnology, 2017, 35, 159-171.	4.9	254
42	The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget, 2016, 7, 24848-24859.	0.8	40
43	Prognostic value of p16 expression in Epsteinâ€Barr virusâ€“positive nasopharyngeal carcinomas. Head and Neck, 2016, 38, E1459-66.	0.9	28
44	Immune Priming of the Tumor Microenvironment by Radiation. Trends in Cancer, 2016, 2, 638-645.	3.8	120
45	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Practical Radiation Oncology, 2016, 6, 241-247.	1.1	41
46	Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Scientific Reports, 2016, 6, 26269.	1.6	167
47	Cerebral Venous Thrombosis Associated with Intracranial Hemorrhage and Timing of Anticoagulation after Hemicraniectomy. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 2312-2316.	0.7	23
48	Non-contiguous meningeal metastases of olfactory neuroblastoma. Journal of Neuro-Oncology, 2016, 126, 201-203.	1.4	13
49	Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma. Oncotarget, 2016, 7, 32156-32171.	0.8	14
50	Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Research and Treatment, 2015, 150, 439-445.	1.1	30
51	Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano, 2015, 9, 8689-8696.	7.3	134
52	Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. Journal of Neuro-Oncology, 2014, 118, 405-412.	1.4	28
53	Pazopanib therapy for cerebellar hemangioblastomas in von Hippelâ€“Lindau disease. Targeted Oncology, 2012, 7, 145-149.	1.7	34
54	Nanomedicine. New England Journal of Medicine, 2010, 363, 2434-2443.	13.9	987

#	Article	IF	Citations
55	Nanoparticle-mediated cellular response is size-dependent. Nature Nanotechnology, 2008, 3, 145-150.	15.6	2,452
56	Biodegradable Quantum Dot Nanocomposites Enable Live Cell Labeling and Imaging of Cytoplasmic Targets. Nano Letters, 2008, 8, 3887-3892.	4.5	116
57	Assessing Near-Infrared Quantum Dots for Deep Tissue, Organ, and Animal Imaging Applications. Journal of the Association for Laboratory Automation, 2008, 13, 6-12.	2.8	30
58	Advances and challenges of nanotechnology-based drug delivery systems. Expert Opinion on Drug Delivery, 2007, 4, 621-633.	2.4	108
59	Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature, 2002, 417, 74-78.	13.7	1,023